Patients with advanced breast cancer who received a combination of Herceptin and Tykerb survived almost five months longer than those who took only Tykerb, doctors reported at the San Antonio Breast Cancer Symposium. Another study presented at the conference suggests that despite the effectiveness of combining Herceptin and anthracyclines, patients had significantly more heart damage and cases of leukemia than a group taking Herceptin and nonanthracyclines.

Related Summaries